These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23808890)

  • 1. Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers.
    Molzan M; Kasper S; Röglin L; Skwarczynska M; Sassa T; Inoue T; Breitenbuecher F; Ohkanda J; Kato N; Schuler M; Ottmann C
    ACS Chem Biol; 2013 Sep; 8(9):1869-75. PubMed ID: 23808890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Raf: a strategic target for therapeutic development against cancer.
    Beeram M; Patnaik A; Rowinsky EK
    J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation.
    Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE
    Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
    Garnett MJ; Rana S; Paterson H; Barford D; Marais R
    Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAS/RAF pathway activation in gliomas: the result of copy number gains rather than activating mutations.
    Jeuken J; van den Broecke C; Gijsen S; Boots-Sprenger S; Wesseling P
    Acta Neuropathol; 2007 Aug; 114(2):121-33. PubMed ID: 17588166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation and role of Raf-1/B-Raf heterodimerization.
    Rushworth LK; Hindley AD; O'Neill E; Kolch W
    Mol Cell Biol; 2006 Mar; 26(6):2262-72. PubMed ID: 16508002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
    Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
    Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
    Roberts PJ; Der CJ
    Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Raf-1 in human pancreatic adenocarcinoma.
    Berger DH; Jardines LA; Chang H; Ruggeri B
    J Surg Res; 1997 Apr; 69(1):199-204. PubMed ID: 9202670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF protein-serine/threonine kinases: structure and regulation.
    Roskoski R
    Biochem Biophys Res Commun; 2010 Aug; 399(3):313-7. PubMed ID: 20674547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas.
    Migliardi G; Sassi F; Torti D; Galimi F; Zanella ER; Buscarino M; Ribero D; Muratore A; Massucco P; Pisacane A; Risio M; Capussotti L; Marsoni S; Di Nicolantonio F; Bardelli A; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2012 May; 18(9):2515-25. PubMed ID: 22392911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signaling from RAS to RAF: The Molecules and Their Mechanisms.
    Jeon H; Tkacik E; Eck MJ
    Annu Rev Biochem; 2024 Aug; 93(1):289-316. PubMed ID: 38316136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raf kinase inhibitors in oncology.
    Strumberg D; Seeber S
    Onkologie; 2005 Feb; 28(2):101-7. PubMed ID: 15665559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells.
    Arthan D; Hong SK; Park JI
    Cancer Lett; 2010 Nov; 297(1):31-41. PubMed ID: 20570039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of upregulated Ras/Raf/ERK1/2 signaling with autism.
    Zou H; Yu Y; Sheikh AM; Malik M; Yang K; Wen G; Chadman KK; Brown WT; Li X
    Genes Brain Behav; 2011 Jul; 10(5):615-24. PubMed ID: 21595826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1.
    Rommel C; Radziwill G; Lovrić J; Noeldeke J; Heinicke T; Jones D; Aitken A; Moelling K
    Oncogene; 1996 Feb; 12(3):609-19. PubMed ID: 8637718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational analysis of the ARAF gene in human cancers.
    Lee JW; Soung YH; Kim SY; Park WS; Nam SW; Min WS; Kim SH; Lee JY; Yoo NJ; Lee SH
    APMIS; 2005 Jan; 113(1):54-7. PubMed ID: 15676015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.